anastrozole has been researched along with Memory Disorders in 6 studies
Memory Disorders: Disturbances in registering an impression, in the retention of an acquired impression, or in the recall of an impression. Memory impairments are associated with DEMENTIA; CRANIOCEREBRAL TRAUMA; ENCEPHALITIS; ALCOHOLISM (see also ALCOHOL AMNESTIC DISORDER); SCHIZOPHRENIA; and other conditions.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Endocrine treatments of breast cancer patients antagonize estrogen and may lead to consequences of estrogen deprivation including menopausal symptoms." | 6.71 | Acute effects of tamoxifen and third-generation aromatase inhibitors on menopausal symptoms of breast cancer patients. ( Ameye, L; Carbonez, A; Christiaens, MR; Morales, L; Neven, P; Paridaens, R; Timmerman, D; Van Huffel, S; Van Limbergen, E; Vergote, I, 2004) |
| ", tamoxifen and anastrozole) on cognitive functioning by comparing 28 postmenopausal women with breast cancer to 37 healthy age-equivalent controls." | 3.76 | Endocrine therapy is associated with low performance on some estrogen-sensitive cognitive tasks in postmenopausal women with breast cancer. ( Crossley, M; Lejbak, L; Vrbancic, M, 2010) |
| "Endocrine treatments of breast cancer patients antagonize estrogen and may lead to consequences of estrogen deprivation including menopausal symptoms." | 2.71 | Acute effects of tamoxifen and third-generation aromatase inhibitors on menopausal symptoms of breast cancer patients. ( Ameye, L; Carbonez, A; Christiaens, MR; Morales, L; Neven, P; Paridaens, R; Timmerman, D; Van Huffel, S; Van Limbergen, E; Vergote, I, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (66.67) | 29.6817 |
| 2010's | 1 (16.67) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Wang, Y | 1 |
| Hao, L | 1 |
| Wang, T | 1 |
| Liu, W | 1 |
| Wang, L | 1 |
| Ju, M | 1 |
| Feng, W | 1 |
| Xiao, R | 1 |
| Lejbak, L | 1 |
| Vrbancic, M | 1 |
| Crossley, M | 1 |
| Jenkins, V | 1 |
| Shilling, V | 1 |
| Fallowfield, L | 1 |
| Howell, A | 1 |
| Hutton, S | 1 |
| Morales, L | 1 |
| Neven, P | 1 |
| Timmerman, D | 1 |
| Christiaens, MR | 1 |
| Vergote, I | 1 |
| Van Limbergen, E | 1 |
| Carbonez, A | 1 |
| Van Huffel, S | 1 |
| Ameye, L | 1 |
| Paridaens, R | 1 |
| Cherrier, MM | 1 |
| Matsumoto, AM | 1 |
| Amory, JK | 1 |
| Ahmed, S | 1 |
| Bremner, W | 1 |
| Peskind, ER | 1 |
| Raskind, MA | 1 |
| Johnson, M | 1 |
| Craft, S | 1 |
| Moradpour, F | 1 |
| Naghdi, N | 1 |
| Fathollahi, Y | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Treating Verbal Memory Deficits Following Chemotherapy for Breast Cancer[NCT03017560] | 45 participants (Actual) | Interventional | 2015-12-31 | Completed | |||
| Role of Testosterone and Its Metabolites Regarding Different Physiological Functions in Subjects Affected by Gender Identity Disorder (FtM Transsexuals)[NCT00146146] | Phase 3 | 15 participants (Actual) | Interventional | 2005-05-31 | Completed | ||
| Testosterone Supplementation in Men With MCI[NCT00539305] | Phase 3 | 22 participants (Actual) | Interventional | 2009-07-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Values represent self evaluation of vigor-activity. The scale compares t-scores of participants to published norms (range 0-100), and higher scores indicate elevated emotion in subscale. Higher t-scores in vigor-activity subscale are considered favorable. Month 3 and Month 6 values display change from baseline. (NCT00539305)
Timeframe: Baseline, 3 and 6 months
| Intervention | units on a scale (Mean) | ||
|---|---|---|---|
| Baseline | Month 3 (Change from Baseline) | Month 6 (Change from Baseline) | |
| Placebo Group | 55.5 | -0.1 | -0.5 |
| Treatment Group | 57.7 | -4.5 | 1.9 |
Values represent total score in Long Delay Word List Recall. Higher score indicates higher level of functioning (range 0-15). Month 3 and Month 6 indicate change from baseline. (NCT00539305)
Timeframe: Baseline, 3 and 6 months
| Intervention | units on a scale (Mean) | ||
|---|---|---|---|
| Baseline | Month 3 (Change from Baseline) | Month 6 (Change from Baseline) | |
| Placebo Group | 4.9 | 0.0 | 1.5 |
| Treatment Group | 6.2 | 2.3 | 0.9 |
Values represent self evaluation of depression (range 0-30). Higher scores indicate a more depressed mood. Month 3 and Month 6 indicate change from baseline. (NCT00539305)
Timeframe: Baseline, Month 3, Month 6
| Intervention | units on a scale (Mean) | ||
|---|---|---|---|
| Baseline | Month 3 (Change from Baseline) | Month 6 (Change from Baseline) | |
| Placebo Group | 4.1 | 2.3 | 2.7 |
| Treatment Group | 7.2 | 0.7 | -2.8 |
Self assessment of Physical Functioning in Health Survey. Higher scores indicate a higher level of functioning (range 0-100). Month 3 and 6 values represent change from baseline in subscale. (NCT00539305)
Timeframe: Baseline, Month 3, Month 6
| Intervention | units on a scale (Mean) | ||
|---|---|---|---|
| Baseline | Month 3 (Change from Baseline) | Month 6 (Change from Baseline) | |
| Placebo Group | 85.6 | -3.8 | -5.4 |
| Treatment Group | 70.7 | 15.0 | 6.4 |
3 trials available for anastrozole and Memory Disorders
| Article | Year |
|---|---|
Does hormone therapy for the treatment of breast cancer have a detrimental effect on memory and cognition? A pilot study.
Topics: Affect; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Anxiet | 2004 |
Acute effects of tamoxifen and third-generation aromatase inhibitors on menopausal symptoms of breast cancer patients.
Topics: Anastrozole; Aromatase Inhibitors; Belgium; Body Mass Index; Breast Neoplasms; Data Interpretation, | 2004 |
The role of aromatization in testosterone supplementation: effects on cognition in older men.
Topics: Aged; Aged, 80 and over; Aging; Anastrozole; Aromatase; Aromatase Inhibitors; Double-Blind Method; E | 2005 |
The role of aromatization in testosterone supplementation: effects on cognition in older men.
Topics: Aged; Aged, 80 and over; Aging; Anastrozole; Aromatase; Aromatase Inhibitors; Double-Blind Method; E | 2005 |
The role of aromatization in testosterone supplementation: effects on cognition in older men.
Topics: Aged; Aged, 80 and over; Aging; Anastrozole; Aromatase; Aromatase Inhibitors; Double-Blind Method; E | 2005 |
The role of aromatization in testosterone supplementation: effects on cognition in older men.
Topics: Aged; Aged, 80 and over; Aging; Anastrozole; Aromatase; Aromatase Inhibitors; Double-Blind Method; E | 2005 |
3 other studies available for anastrozole and Memory Disorders
| Article | Year |
|---|---|
27-Hydroxycholesterol-Induced Dysregulation of Cholesterol Metabolism Impairs Learning and Memory Ability in ApoE ε4 Transgenic Mice.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Anastrozole; Animals; Apolipoprotein A-I; Apolipoprotein E | 2022 |
Endocrine therapy is associated with low performance on some estrogen-sensitive cognitive tasks in postmenopausal women with breast cancer.
Topics: Aged; Anastrozole; Breast Neoplasms; Case-Control Studies; Cognition Disorders; Estrogen Antagonists | 2010 |
Anastrozole improved testosterone-induced impairment acquisition of spatial learning and memory in the hippocampal CA1 region in adult male rats.
Topics: Analysis of Variance; Anastrozole; Animals; Aromatase Inhibitors; Discrimination Learning; Escape Re | 2006 |